Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results
March 29, 2023 08:05 ET
|
Third Harmonic Bio
SAN FRANCISCO, March 29, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria
December 15, 2022 07:00 ET
|
Third Harmonic Bio
-- Company decision follows observation of asymptomatic liver transaminitis in two subjects enrolled in first dose cohort of 200mg BID -- Evidence of clinical activity observed; full data set to be...
Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference
November 21, 2022 16:05 ET
|
Third Harmonic Bio
CAMBRIDGE, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for allergy and...
Third Harmonic Bio Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 09, 2022 16:15 ET
|
Third Harmonic Bio
Successfully Completed Upsized Initial Public Offering Providing Funding Through 2025 Patient Dosing Underway in Phase 1b Chronic Inducible Urticaria Clinical Trial CAMBRIDGE, Mass., Nov. 09, 2022 ...
Third Harmonic Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
September 19, 2022 16:10 ET
|
Third Harmonic Bio
CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for...
Third Harmonic Bio Announces Pricing of Upsized Initial Public Offering
September 14, 2022 19:33 ET
|
Third Harmonic Bio
CAMBRIDGE, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for...
Third Harmonic Bio Appoints Thomas M. Soloway to its Board of Directors
August 09, 2022 08:30 ET
|
Third Harmonic Bio
CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment...
Julie Person Joins Third Harmonic Bio as Chief Administrative Officer
June 28, 2022 14:14 ET
|
Third Harmonic Bio
CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of...